Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILB2109 in advanced solid malignancies
NCT05278546Phase 1Active, not recruiting
- Sponsor
- Innolake Biopharm
- Start
- Apr 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ILB-2109 in solid tumor, sponsored by Innolake Biopharm. Primary endpoints: The Incidence of Dose Limiting Toxicities (DLTs), Maximum Tolerated Dose at 30 Months and 1 more. Started Apr 2022; status: active, not recruiting.
02
Drugs
ILB-2109
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05278546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05278546.